Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
geptanolimab + fruquintinib
- Development stage
- Phase 1
- Lead developer
- EddingGenor Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Geptanolimab + fruquintinib** is a combination therapy currently being investigated for the treatment of metastatic colorectal cancer (mCRC)[3][5][7]. **Geptanolimab** is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), acting as a checkpoint inhibitor to enhance anti-tumor immune responses. **Fruquintinib** is an orally administered small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), blocking angiogenesis and tumor growth[1][4][6]. The combination aims to improve therapeutic efficacy through synergistic effects: fruquintinib's anti-angiogenic action may remodel the tumor microenvironment to make it more responsive to immunotherapy with geptanolimab[5]. Early clinical studies suggest manageable safety and promising anti-tumor activity[3][7]. Primary indication is metastatic colorectal cancer; development is supported by multicenter phase Ib trials[3][7].
- Other names
- geptanolimab + fruquintinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on geptanolimab + fruquintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on geptanolimab + fruquintinib.